TY - JOUR
T1 - Case report
T2 - olaparib use in metastatic lung adenocarcinoma with BRCA2 pathogenic variant
AU - Soon Jian Hao, Jonathan
AU - Hoai, Chan Sock
AU - Weng, Daniel Tan Shao
AU - Ngeow, Joanne
AU - Chiang, Jianbang
N1 - Publisher Copyright:
© 2022 Soon Jian Hao et al.; Published by Cold Spring Harbor Laboratory Press.
PY - 2022/12/1
Y1 - 2022/12/1
N2 - Poly (ADP-ribose) polymerase (PARP) inhibitors have been approved in malignancies associated with germline BRCA1 or BRCA2 pathogenic variants, such as breast, ovarian, prostate, and pancreatic cancer. In malignancies not associated with germline BRCA1 or BRCA2 pathogenic variants, the therapeutic relevance of PARP inhibitors is less clear. Non-small-cell lung cancer (NSCLC) is known to demonstrate somatic alterations in BRCA1 or BRCA2 gene. The current report is on a gentleman with metastatic lung adenocarcinoma with a somatic BRCA2 pathogenic variant, who was effectively treated with olaparib. Furthermore, we discuss the existing data for use of PARP inhibitors in NSCLC. This study highlights the utility of next-generation sequencing in identifying gene mutations and demonstrates how such information can be used to select targeted therapies in patients with actionable molecular alterations.
AB - Poly (ADP-ribose) polymerase (PARP) inhibitors have been approved in malignancies associated with germline BRCA1 or BRCA2 pathogenic variants, such as breast, ovarian, prostate, and pancreatic cancer. In malignancies not associated with germline BRCA1 or BRCA2 pathogenic variants, the therapeutic relevance of PARP inhibitors is less clear. Non-small-cell lung cancer (NSCLC) is known to demonstrate somatic alterations in BRCA1 or BRCA2 gene. The current report is on a gentleman with metastatic lung adenocarcinoma with a somatic BRCA2 pathogenic variant, who was effectively treated with olaparib. Furthermore, we discuss the existing data for use of PARP inhibitors in NSCLC. This study highlights the utility of next-generation sequencing in identifying gene mutations and demonstrates how such information can be used to select targeted therapies in patients with actionable molecular alterations.
KW - chronic lung disease
UR - http://www.scopus.com/inward/record.url?scp=85145050982&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85145050982&partnerID=8YFLogxK
U2 - 10.1101/mcs.a006223
DO - 10.1101/mcs.a006223
M3 - Article
C2 - 36577523
AN - SCOPUS:85145050982
SN - 2373-2873
VL - 8
JO - Cold Spring Harbor molecular case studies
JF - Cold Spring Harbor molecular case studies
IS - 7
ER -
